Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Siemens Publicly Lists Healthcare Business

By Sanjit Dutt
Posted on 14 Nov 2016
Siemens AG (Munich, Germany), Europe’s largest industrial conglomerate, has announced that its USD 15 billion healthcare division, which operates under the uniform brand name Siemens Healthineers (Erlangen, Germany), will be publicly listed as an independent medical technology business.

In May 2014, Siemens had announced its intention to set up its healthcare business as a "company within the company" so that the business could adjust to transformations in the healthcare market in a flexible and focused manner with its own market presence. More...
Siemens Healthineers focuses on the therapeutic and molecular diagnostic market, and offers medical imaging, laboratory diagnostics, and management, consulting and digital services. It is currently working with Pfizer to develop in vitro diagnostic tests for improving patient selection, treatment monitoring and dosing in clinical trials, as well as with ViiV Healthcare for developing diagnostics for its first-in-class HIV drug Celsentri (maraviroc).

Siemens has not yet provided any details about the planned scope and timing regarding the initial public offering of its healthcare business, but expects the move to encourage investors and provide a foundation for any future acquisitions or investments. "Healthcare technology is a highly attractive business in which we want to further expand our leading position. With this step, we continue to implement Vision 2020 launched in May 2014. The public listing will give Healthineers even more focus and flexibility in pursuing its growth strategy," said Joe Kaeser, President and CEO of Siemens AG. "The public listing is now the next step in further strengthening Siemens Healthineers in Siemens for the future. We're implementing this from an already leading position. Siemens Healthineers has already increased its market share and has an outstanding portfolio of top technologies that we're further developing," added Kaeser.

"The public listing is a key lever for reaching our strategic goal of being THE enabler for healthcare providers worldwide," said Bernd Montag, CEO of Siemens Healthineers. "Greater entrepreneurial freedom and agility will allow us to help shape the development of the global healthcare market and the growth strategies of successful healthcare providers. We'll enable our customers to participate successfully in the trends toward consolidation, industrialization and holistic health management with a high degree of clinical relevance, efficient workflows and financial value added."

Related Links:
Siemens
Siemens Healthineers

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.